Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) - Pipeline Review, H1 2016

  • ID: 3775431
  • Drug Pipelines
  • 96 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Akari Therapeutics, Plc
  • Amgen Inc.
  • InflaRx GmbH
  • Novartis AG
  • Noxxon Pharma AG
  • Ophthotech Corp.
  • MORE
Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) - Pipeline Review, H1 2016

Summary

‘Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) - Pipeline Review, H1 2016’, provides in depth analysis on Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) targeted pipeline therapeutics.

The report provides comprehensive information on the Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4)
- The report reviews Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Akari Therapeutics, Plc
  • Amgen Inc.
  • InflaRx GmbH
  • Novartis AG
  • Noxxon Pharma AG
  • Ophthotech Corp.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Overview

Therapeutics Development

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) - Products under Development by Stage of Development

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) - Products under Development by Therapy Area

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) - Products under Development by Indication

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Unknown Stage Products

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) - Products under Development by Companies

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) - Products under Development by Universities/Institutes

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) - Companies Involved in Therapeutics Development

Akari Therapeutics, Plc

Alexion Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

Amgen Inc.

Epirus Biopharmaceuticals, Inc.

InflaRx GmbH

Novartis AG

Noxxon Pharma AG

Ophthotech Corp.

Ra Pharmaceuticals, Inc.

Swedish Orphan Biovitrum AB

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) - Drug Profiles

AcPepA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALN-CC5 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALXN-1007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALXN-1210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALXN-5500 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avacincaptad pegol sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bikaciomab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BikajuMab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Coversin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eculizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eculizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eculizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IFX-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IFX-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Ischemia Reperfusion Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NM-9405 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOXD-21 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Inhibit Complement C5 for Immunology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RA-101295 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RA-101348 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RA-101495 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOBI-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit Complement Component 5a for Chronic Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tesidolumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) - Dormant Projects

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) - Discontinued Products

Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) - Featured News & Press Releases

Jun 07, 2016: InflaRx initiates phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients undergoing complex cardiac surgery

Jun 06, 2016: Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis (gMG)

Jun 03, 2016: Alnylam to Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data

Jun 01, 2016: European Commission Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

May 23, 2016: Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Guillain Barré Syndrome

May 19, 2016: Researchers to Present Additional Data, Including Late-Breaking Results on ALXN1007 in Patients with GI-GVHD at EHA Annual Congress

May 19, 2016: Akari Therapeutics Announces Upcoming Data Presentation at the 21st European Hematology Association Annual Congress and Update on First PNH Patient Treated

May 19, 2016: Researchers to Present Late-Breaking Data on ALXN1210 in Patients with PNH at EHA Annual Congress

May 19, 2016: Ra Pharmaceuticals to Present at the 21st Congress of the European Hematology Association

May 12, 2016: Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Guillain Barré Syndrome

May 09, 2016: EPIRUS Announces Reprioritization of Pipeline, to focus on biosimilar product BOW080

Mar 31, 2016: Akari Therapeutics Announces Positive Preliminary Results from First PNH Patient Treated With Coversin

Feb 16, 2016: A Statement from the Executive Officer of the Ontario Public Drug Programs on behalf of the pCPA

Jan 29, 2016: Akari Therapeutics Receives Approval From the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial

Jan 28, 2016: InflaRx announces positive phase IIa top-line results from the SCIENS trial investigating IFX-1, a first-in-class anti-complement C5a antibody

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Akari Therapeutics, Plc, H1 2016

Pipeline by Alexion Pharmaceuticals, Inc., H1 2016

Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016

Pipeline by Amgen Inc., H1 2016

Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016

Pipeline by InflaRx GmbH, H1 2016

Pipeline by Novartis AG, H1 2016

Pipeline by Noxxon Pharma AG, H1 2016

Pipeline by Ophthotech Corp., H1 2016

Pipeline by Ra Pharmaceuticals, Inc., H1 2016

Pipeline by Swedish Orphan Biovitrum AB, H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Akari Therapeutics, Plc
  • Amgen Inc.
  • InflaRx GmbH
  • Novartis AG
  • Noxxon Pharma AG
  • Ophthotech Corp.
  • MORE
According to our recently published report 'Complement C5 – Pipeline Review, H1 2016'; Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) pipeline Target constitutes close to 24 molecules. Out of which approximately 21 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the publisher says; Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) Complement component 5 is a protein is encoded by the C5 gene. Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.

The report 'Complement C5 – Pipeline Review, H1 2016' outlays comprehensive information on the Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Complement C5 (C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 6, 3 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Note: Product cover images may vary from those shown
5 of 6
Akari Therapeutics, Plc
Alexion Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Amgen Inc.
Epirus Biopharmaceuticals, Inc.
InflaRx GmbH
Novartis AG
Noxxon Pharma AG
Ophthotech Corp.
Ra Pharmaceuticals, Inc.
Swedish Orphan Biovitrum AB
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll